CA1171787A - Wound treating agent in powder form and process for its preparation - Google Patents
Wound treating agent in powder form and process for its preparationInfo
- Publication number
- CA1171787A CA1171787A CA000386455A CA386455A CA1171787A CA 1171787 A CA1171787 A CA 1171787A CA 000386455 A CA000386455 A CA 000386455A CA 386455 A CA386455 A CA 386455A CA 1171787 A CA1171787 A CA 1171787A
- Authority
- CA
- Canada
- Prior art keywords
- gellable
- treating agent
- wound treating
- reagent
- acid derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Abstract
ABSTRACT
The present invention provides a wound treating agent in powder form based on a sweallable organic polymer, which comprises a cross-linked polymer of a hydrophillic acrylic or methacrylic acid derivative.
which polymer is permeated by a gellable polysaccharide and/or protein or polypeptide, the agent being obtain-able by polymerising a hydrophilic acrylic or meth-acrylic acid derivative in the presence of a dissolved, gellable polysaccharide and/or protein or polypeptide and of a cross-linking agent.
The present invention also provides a process for the production of this wound treating agent, wherein a hydrophilic acrylic or methacrylic acid derivative is polymerised in an aqueous solution of a gellable polysaccharide and/or protein or polypeptide in the presence of a cross-linking agent and of a conventional polymerisation initiator, to give a transparent gel which is dried and pulverised.
The present invention provides a wound treating agent in powder form based on a sweallable organic polymer, which comprises a cross-linked polymer of a hydrophillic acrylic or methacrylic acid derivative.
which polymer is permeated by a gellable polysaccharide and/or protein or polypeptide, the agent being obtain-able by polymerising a hydrophilic acrylic or meth-acrylic acid derivative in the presence of a dissolved, gellable polysaccharide and/or protein or polypeptide and of a cross-linking agent.
The present invention also provides a process for the production of this wound treating agent, wherein a hydrophilic acrylic or methacrylic acid derivative is polymerised in an aqueous solution of a gellable polysaccharide and/or protein or polypeptide in the presence of a cross-linking agent and of a conventional polymerisation initiator, to give a transparent gel which is dried and pulverised.
Description
439b 1 ~717~37 The present invention is concerned with wound treating agents in powder form and with the production thereof.
T~ound treating agents in the form of swellable dry powders of organic polymers are already known.
one known agent of this kind consists of dry, hydro-philic particles which are a three-dimensional mesh of dextran molecules and, when applied to weeping wounds, they absorb the wound exudate and swell to form a gel-like layer, scab formation hereby also being said to be prevented. Such a wound dressing powder sucks up bacteria due to the capillary forces between the particles. This admittedly results in a ~ucking up of bacteria from the base of the wound but, on the other hand, it also makes possible the penetration of bacteria from the outside and thus cannot prevent the occurrence of infections. Furthermore, due to its particulate form, it i~ often difficult completely to remove the agent again from the wounds, although this would be necessary.
Therefore, there is a need for a swellable, granulated wound treating powder which, on the one hand, has a strong absorbing power and, during the absorbing phase, also removes bacteria from the infected base of the wound but which, on the other hand, when, in a swollen state, displays a good adhesion between the swollen particles so that it can .~
1~';'17~7 easily be removed from the wound as a more or less coherent mass and, at the same time, makes difficult the penetration of bacteria from the outside to the inside.
Initially, it appears to be impossible to com-bine both apparently mutually opposed properties in one material, namely, fine particularity and high absorbency, on the one hand, and impenetrability for bacteria and high cohesion, on the other hand.
Surprisingly, however, we have found that it is possible to solve this problem and to provide a powdered wound treating agent which combined all these properties~
the solution of thi~ problem using, as a starting point, the invention described in Federal Republic of Germany Patent Specification No.28 49 570.
Federal Republic of Germany Patent Specification No.28 49 570 discloses a transparent liquid dressing material, which is especially useful for the treatment of wounds, comprising a hydrophilic organic transparent gel in sheet of strip form, which is present as a dry, swellable, clear foil and which can contain buffer substances, active materials conventional in the treat-ment of wound~, nutrients and/or growth materials and optionally a filamentary or mesh-like strengthening material.
According to a preferred embodiment of the dressing material according to Federal Republic of Germany Patent Specilication No.2;~ 49 570, the gel consists of a geliable polysaccharide and/or protein or poly~eptide and a polymer of a hydrophilic acrylic or methacrylic acid derivative, the gel having been produced by polymerisation of the acrylic or meth-acrylic acid derivative in the presence of the poly-saccharide and/or protein or polypeptide.
~ Je have now found that, on the basis of this dry, swellable gel foil, a powdered wound treating agent can be provided which displays surprising and advantageous properties and opens up new possibilities of use.
~ hus, according to the present invention, t'nere is provided a wound treating agent in powder form based on a swellable organic polymer, which comprises a cross-linked polymer of a hydrophilic acrylic or methacrylic acid derivative, which polymer is permeated by a gellable polysaccharide and/or protein or poly-peptide, the agent being obtainable by the polymerising of a hydrophilic acrylic or methacrylic acid derivative in the presence of a dissolved gellable polysaccharide and/or protein or polypeptide and of a cross-linking agent.
The absorbency of the powder according to the present invention exceeds that of the known powdered wound treating agents and its ability to take up water is several times greater than that of the known powders.
17~7 t -5-Simultaneously, however, the swollen particles "stick"
together in such a manner that they not only form a coherent mass which can easily be removed again from the wound but also form a barrier which is impermeable to bacteria and bar~ the entry of pathogens to the wound.
The hydrophilic acrylic or methacrylic acid derivative, upon which the polymer of the wound treat-ing agent according to the present invention is based, is preferably an amide or ester, the latter containing the re~idue of an alkanol which possibly still has one or more additional free hydroxyl groups. Agarose is the preferred polysaccharide and gelatine is the pre-ferred protein.
With regard to the composition of the agent, the amount of polymer and of saccharide, protein or poly-peptide can vary within wide limits. However, a com-position is preferred which contains 50 to 90/0 by weight of polymerised acrylic or methacrylic acid derivative and 50 to 10% by weight of polysaccharide and/or protein. In the case of this preferred compos-ition, the wound treating agent displays a water take-up of at least ~0 ml./g., determined by allowing it to swell for t~o minutes in salt-free water and preferably in distilled water.
In the case of an e~pecially preferred embodiment, the wound treating agent according to the present ~1 ~ 1787 invention contains 50 to 7~O ~y weight of cross-linked polyacrylamide and 50 to 3~/O by weight of gelatine.
In the case of this composition, a water take-up of up to 40 ml./g. can be achieved under the above-mentioned conditions.
In contradistinction thereto, the water take-up under the same conditions of a commercially available wound treating agent based on organic polymers is about 5 ml./g.
The cross-linking agent is added in an amount such that the desired swellability is maintained. In general, very good swellabilities are obtained when using about 0.5 to about 5 mol.% of cross-linking agent, referred to the monomer employed, especially favourable results being achieved with 1 to 2 mol %
of cross-linking agent. When using acrylamide as the monomer and methylene-bis-acrylamide as the cross-linking agent, this means about 20 to 40 mg. of methylene-bis-acrylamide per gram of acrylamide.
The wound treating powder according to the present invention, when in a swollen state, develops so great an adhesive force that, in most cases, it can be com-pletely removed from the wound by rinsing out. In the swollen state, the gel is sufficiently transparent in order to permit assessment of the colour of the base of the wound through the gel.
The production of the wound treating agent i~'~l'7~7 -7- ;
according to the present invention is carried out, as described in Federal Republic of Germany Patent Specification No.2~ 49 570, by dryin~ a gel of a particular composition and su~sequently comminuting is by grinding or pulverising. In order to obtain a complete and rapid drying, the gel is preferably used in comminuted fonm, for which purpose there can be used not only the foil form but also a granulation of the gel. In this comminuted form, the gel can also be rapidly washed free of low molecu~ar weight components before drying.
The drying itself can be carried out at any desired temperature bet~een ambient temperature and about 120C., drying preferably being carried out to a residual water content of less than 10% by weight.
However, above 90C., the drying results in a consider-able reduction of the ability of the agent to take up liquid. Especially good results have been obtained by drying at a temperature of from 40 to 80C. For the drying itself, there otherwise correspondingly apply the statements made in Federal Republic of Germany Patent Specification No.28 49 570.
The parti~le 3ize of the powder according to the present invention influences the swelling properties.
With decreasing particle size, the rate of liquid take-up increases and, to a lesser extent, also the amount of liquid which can be taken up. In general, a particle ~t 71~87 s~ ' size is preferred in which the swelling is substant-ially concluded between about 0.5 and about 5 minutes, wh~ch normally applies in the case of particle sizes of from 0.05 mm. to 0.5 mm. By means of the use of finer or coarser particles, the rate of swelling can, if desired, also be adjusted outside of this range and thereby made greater or smaller. For adjusted properties with regard to the rate of swelling, trans-parency, cohesion and bacterial impenetrability, mixtures of different particle sizes in the given range are especially preferred.
The wound treating powder according to the present invention can be applied as such to wounds.
Alternatively, it is also possible first to con~ert the powder with a limited amount of liquid into a paste-like consistency and to apply the ~o obtained gel paste. Syringes are particularly suitable for applying the paste. Application with a syringe con-taining such a gel paste is very simple in a hospital.
The gel is extruded on to and into the wound and left there as long as appears to be expedient. For this purpose, pre-filled sterile ready-to-use syringes can also be employed. As liquids, there can be used solutions which are conventional in the treatment of wounds, especially physiological solutions, water-containing mixtures, for example with mono- or poly-hyd-oxy alcohols, such as glycerol, or other organic liq-~ids, which can contain the substances mentioned in Federal ~epublic of Germany Patent Specification No.?~ 43 570, such as medicaments, nutrients, disin-fection agents, growth materials, salts, buffer sub-stances and the agents conventionally used in wound healing, dissolved therein.
The powder according to the present invention can also be used for the qualitative and quantitative determination of low molecular weight substances secreted by wounds. For this purpose, the material taken up is eluted by the methods used in molecular sieve technology, for example by washing out with a salt gradient and analysis of the eluted material.
In order to prevent a contamination by undissolved particle~ from the wounds, the powder can be enclosed in a semi-permeable membrane which is only permeable to dissolved substances or to low molecular weight substances. Depending upon the desired degree of exclusion, for this purpose there can be used con-ventional dialysis foils or ultrafiltration foils.
Bacteria-impermeable fabrics can also be used. Such powder-containing sachetq are applied as such to wounds and, after sucking up the secretum, are removed, opened and the powder investigated in the above-described manner.
1 ~ ~ 1787 The followinq E~amples are given for the purpose of illustrating the present invention:-Example 1.
Production of a drv qel powder.
As described in Example 2 of Federal Republic of Germany Patent Specification ~o.27 25 261, starting from 3.2 g. acrylamide, 82 mg. bis-acrylamide and 2 g.
agar-agar or agarose, there was produced a gel plate with a thickness of 3 mm. After washing out, it was dried in a drying cabinet for 24 hours at 50C. The so obtained brittle, dried foil was then ground in a ball mill to an average particle size of less than 0.2 mm. The so obtained product, when swollen in distilled water for 2 minutes, had a water take-up of 40 ml./g.
The drying of the gel plate was repeated, dryinq being carried out for 30 minutes at a temperature of 100C. After 2 minutes, the water take-up was 22 ml./g.
and after 10 minutes was 28 ml./g.
In a 0.9% aqueous sodium chloride solution, the water take-up after 2 minutes was 22 ml./g. in the case of a powder which had been dried at 50C.
The determination of the water take-up was carried out by placing 10 ml. distilled water in a 25 ml. gla~s beaker, weighing it and immersing 100 mg. of dry gel powder in a nylon sieve vessel in the water for 2 minutes.
The nylon sieve vessel was then removed and the weight l.t'717~7 difference of the glass beaker was determined in comparison with the weight before the i~mer~ion.
Example 2.
As described in Example 1 of Federal Republic of Germany Patent Specification No.~7 25 261, start-ing from 5 g. acrylamide, 5 g. gelatine and 130 mg.
~,N'-methylene-bis-acrylamide, there was produced a gel plate with a thickness of 3 mm. After washing out the gel plate, it was dried for 60 hours at 70C.
in a drying cabinet. The so obtained dry foil was ground as described in Example 1. The properties of the product corresponded to those of the powder des-cribed in Example 1.
Example 3.
A gel according to Example 1 was swollen in nutrient broth and inoculated in a test tube with Serratia marcescens. As a comparison, the same amount of bacteria was introduced into a test tube with nutrient broth alone. After 2 days incubation, the nutrient broth without gel is non-transparent, reddish and thi^kly grown with bacteria, whereas the test tube with gel only shows bacterial growth in the uppermost layer. This shows that the powdered gel according to the present invention, when swollen, makes the pene-tration of bacteria very difficult or impossible.
Example 4.
A dry gel powder according to the present invention -~2-and produced as described in Example 1 was classified with a sieve, four fractions thereby beinq obtained.
Fraction 1 consisted of a portion which did not pass a sieve of 57~ apertures/cm~ (about 0.~5 mm. aperture width), fraction 2 consisted of particles which passed a 576 aperture sieve but were retained by a 900 aperture/
cm sieve (about 0.20 mm. aperture width), fraction 3 passed a 900 aperture sieve and was retained by a 1600 aperture sieve (about O.lS mm. aperture width) and fraction 4 consisted of particles which passed a 1600 aperture sieve.
For each of these our fractions and for the starting mixture, there was determined the water take-up for, in each case, 1 g. of powder in dependence upon the time, the results obtained being summarised in the Figure of the accompanying drawing which shows graphic-ally the water take-up in ml./g., plotted against the time in minutes. Curves 1 to 4 correspond to the water take-up of fractions 1 to 4 and curve 5 shows the water take-up of the non-fractionated mixture. The latter contained ~8.1% by weight of fraction 1, 9.4% by weight of fraction 2, 11.4% by weight of fraction 3 and 12.1%
by weight of fraction 4. As can be seen from the curves, the rate of water take-up in the case of fraction 4 was, in the initial phase, about twice as great as in the case of fraction 1, whereas the total water take-up after 5 minutes amounts to 38.3 and 34.3 g., respectively.
T~ound treating agents in the form of swellable dry powders of organic polymers are already known.
one known agent of this kind consists of dry, hydro-philic particles which are a three-dimensional mesh of dextran molecules and, when applied to weeping wounds, they absorb the wound exudate and swell to form a gel-like layer, scab formation hereby also being said to be prevented. Such a wound dressing powder sucks up bacteria due to the capillary forces between the particles. This admittedly results in a ~ucking up of bacteria from the base of the wound but, on the other hand, it also makes possible the penetration of bacteria from the outside and thus cannot prevent the occurrence of infections. Furthermore, due to its particulate form, it i~ often difficult completely to remove the agent again from the wounds, although this would be necessary.
Therefore, there is a need for a swellable, granulated wound treating powder which, on the one hand, has a strong absorbing power and, during the absorbing phase, also removes bacteria from the infected base of the wound but which, on the other hand, when, in a swollen state, displays a good adhesion between the swollen particles so that it can .~
1~';'17~7 easily be removed from the wound as a more or less coherent mass and, at the same time, makes difficult the penetration of bacteria from the outside to the inside.
Initially, it appears to be impossible to com-bine both apparently mutually opposed properties in one material, namely, fine particularity and high absorbency, on the one hand, and impenetrability for bacteria and high cohesion, on the other hand.
Surprisingly, however, we have found that it is possible to solve this problem and to provide a powdered wound treating agent which combined all these properties~
the solution of thi~ problem using, as a starting point, the invention described in Federal Republic of Germany Patent Specification No.28 49 570.
Federal Republic of Germany Patent Specification No.28 49 570 discloses a transparent liquid dressing material, which is especially useful for the treatment of wounds, comprising a hydrophilic organic transparent gel in sheet of strip form, which is present as a dry, swellable, clear foil and which can contain buffer substances, active materials conventional in the treat-ment of wound~, nutrients and/or growth materials and optionally a filamentary or mesh-like strengthening material.
According to a preferred embodiment of the dressing material according to Federal Republic of Germany Patent Specilication No.2;~ 49 570, the gel consists of a geliable polysaccharide and/or protein or poly~eptide and a polymer of a hydrophilic acrylic or methacrylic acid derivative, the gel having been produced by polymerisation of the acrylic or meth-acrylic acid derivative in the presence of the poly-saccharide and/or protein or polypeptide.
~ Je have now found that, on the basis of this dry, swellable gel foil, a powdered wound treating agent can be provided which displays surprising and advantageous properties and opens up new possibilities of use.
~ hus, according to the present invention, t'nere is provided a wound treating agent in powder form based on a swellable organic polymer, which comprises a cross-linked polymer of a hydrophilic acrylic or methacrylic acid derivative, which polymer is permeated by a gellable polysaccharide and/or protein or poly-peptide, the agent being obtainable by the polymerising of a hydrophilic acrylic or methacrylic acid derivative in the presence of a dissolved gellable polysaccharide and/or protein or polypeptide and of a cross-linking agent.
The absorbency of the powder according to the present invention exceeds that of the known powdered wound treating agents and its ability to take up water is several times greater than that of the known powders.
17~7 t -5-Simultaneously, however, the swollen particles "stick"
together in such a manner that they not only form a coherent mass which can easily be removed again from the wound but also form a barrier which is impermeable to bacteria and bar~ the entry of pathogens to the wound.
The hydrophilic acrylic or methacrylic acid derivative, upon which the polymer of the wound treat-ing agent according to the present invention is based, is preferably an amide or ester, the latter containing the re~idue of an alkanol which possibly still has one or more additional free hydroxyl groups. Agarose is the preferred polysaccharide and gelatine is the pre-ferred protein.
With regard to the composition of the agent, the amount of polymer and of saccharide, protein or poly-peptide can vary within wide limits. However, a com-position is preferred which contains 50 to 90/0 by weight of polymerised acrylic or methacrylic acid derivative and 50 to 10% by weight of polysaccharide and/or protein. In the case of this preferred compos-ition, the wound treating agent displays a water take-up of at least ~0 ml./g., determined by allowing it to swell for t~o minutes in salt-free water and preferably in distilled water.
In the case of an e~pecially preferred embodiment, the wound treating agent according to the present ~1 ~ 1787 invention contains 50 to 7~O ~y weight of cross-linked polyacrylamide and 50 to 3~/O by weight of gelatine.
In the case of this composition, a water take-up of up to 40 ml./g. can be achieved under the above-mentioned conditions.
In contradistinction thereto, the water take-up under the same conditions of a commercially available wound treating agent based on organic polymers is about 5 ml./g.
The cross-linking agent is added in an amount such that the desired swellability is maintained. In general, very good swellabilities are obtained when using about 0.5 to about 5 mol.% of cross-linking agent, referred to the monomer employed, especially favourable results being achieved with 1 to 2 mol %
of cross-linking agent. When using acrylamide as the monomer and methylene-bis-acrylamide as the cross-linking agent, this means about 20 to 40 mg. of methylene-bis-acrylamide per gram of acrylamide.
The wound treating powder according to the present invention, when in a swollen state, develops so great an adhesive force that, in most cases, it can be com-pletely removed from the wound by rinsing out. In the swollen state, the gel is sufficiently transparent in order to permit assessment of the colour of the base of the wound through the gel.
The production of the wound treating agent i~'~l'7~7 -7- ;
according to the present invention is carried out, as described in Federal Republic of Germany Patent Specification No.2~ 49 570, by dryin~ a gel of a particular composition and su~sequently comminuting is by grinding or pulverising. In order to obtain a complete and rapid drying, the gel is preferably used in comminuted fonm, for which purpose there can be used not only the foil form but also a granulation of the gel. In this comminuted form, the gel can also be rapidly washed free of low molecu~ar weight components before drying.
The drying itself can be carried out at any desired temperature bet~een ambient temperature and about 120C., drying preferably being carried out to a residual water content of less than 10% by weight.
However, above 90C., the drying results in a consider-able reduction of the ability of the agent to take up liquid. Especially good results have been obtained by drying at a temperature of from 40 to 80C. For the drying itself, there otherwise correspondingly apply the statements made in Federal Republic of Germany Patent Specification No.28 49 570.
The parti~le 3ize of the powder according to the present invention influences the swelling properties.
With decreasing particle size, the rate of liquid take-up increases and, to a lesser extent, also the amount of liquid which can be taken up. In general, a particle ~t 71~87 s~ ' size is preferred in which the swelling is substant-ially concluded between about 0.5 and about 5 minutes, wh~ch normally applies in the case of particle sizes of from 0.05 mm. to 0.5 mm. By means of the use of finer or coarser particles, the rate of swelling can, if desired, also be adjusted outside of this range and thereby made greater or smaller. For adjusted properties with regard to the rate of swelling, trans-parency, cohesion and bacterial impenetrability, mixtures of different particle sizes in the given range are especially preferred.
The wound treating powder according to the present invention can be applied as such to wounds.
Alternatively, it is also possible first to con~ert the powder with a limited amount of liquid into a paste-like consistency and to apply the ~o obtained gel paste. Syringes are particularly suitable for applying the paste. Application with a syringe con-taining such a gel paste is very simple in a hospital.
The gel is extruded on to and into the wound and left there as long as appears to be expedient. For this purpose, pre-filled sterile ready-to-use syringes can also be employed. As liquids, there can be used solutions which are conventional in the treatment of wounds, especially physiological solutions, water-containing mixtures, for example with mono- or poly-hyd-oxy alcohols, such as glycerol, or other organic liq-~ids, which can contain the substances mentioned in Federal ~epublic of Germany Patent Specification No.?~ 43 570, such as medicaments, nutrients, disin-fection agents, growth materials, salts, buffer sub-stances and the agents conventionally used in wound healing, dissolved therein.
The powder according to the present invention can also be used for the qualitative and quantitative determination of low molecular weight substances secreted by wounds. For this purpose, the material taken up is eluted by the methods used in molecular sieve technology, for example by washing out with a salt gradient and analysis of the eluted material.
In order to prevent a contamination by undissolved particle~ from the wounds, the powder can be enclosed in a semi-permeable membrane which is only permeable to dissolved substances or to low molecular weight substances. Depending upon the desired degree of exclusion, for this purpose there can be used con-ventional dialysis foils or ultrafiltration foils.
Bacteria-impermeable fabrics can also be used. Such powder-containing sachetq are applied as such to wounds and, after sucking up the secretum, are removed, opened and the powder investigated in the above-described manner.
1 ~ ~ 1787 The followinq E~amples are given for the purpose of illustrating the present invention:-Example 1.
Production of a drv qel powder.
As described in Example 2 of Federal Republic of Germany Patent Specification ~o.27 25 261, starting from 3.2 g. acrylamide, 82 mg. bis-acrylamide and 2 g.
agar-agar or agarose, there was produced a gel plate with a thickness of 3 mm. After washing out, it was dried in a drying cabinet for 24 hours at 50C. The so obtained brittle, dried foil was then ground in a ball mill to an average particle size of less than 0.2 mm. The so obtained product, when swollen in distilled water for 2 minutes, had a water take-up of 40 ml./g.
The drying of the gel plate was repeated, dryinq being carried out for 30 minutes at a temperature of 100C. After 2 minutes, the water take-up was 22 ml./g.
and after 10 minutes was 28 ml./g.
In a 0.9% aqueous sodium chloride solution, the water take-up after 2 minutes was 22 ml./g. in the case of a powder which had been dried at 50C.
The determination of the water take-up was carried out by placing 10 ml. distilled water in a 25 ml. gla~s beaker, weighing it and immersing 100 mg. of dry gel powder in a nylon sieve vessel in the water for 2 minutes.
The nylon sieve vessel was then removed and the weight l.t'717~7 difference of the glass beaker was determined in comparison with the weight before the i~mer~ion.
Example 2.
As described in Example 1 of Federal Republic of Germany Patent Specification No.~7 25 261, start-ing from 5 g. acrylamide, 5 g. gelatine and 130 mg.
~,N'-methylene-bis-acrylamide, there was produced a gel plate with a thickness of 3 mm. After washing out the gel plate, it was dried for 60 hours at 70C.
in a drying cabinet. The so obtained dry foil was ground as described in Example 1. The properties of the product corresponded to those of the powder des-cribed in Example 1.
Example 3.
A gel according to Example 1 was swollen in nutrient broth and inoculated in a test tube with Serratia marcescens. As a comparison, the same amount of bacteria was introduced into a test tube with nutrient broth alone. After 2 days incubation, the nutrient broth without gel is non-transparent, reddish and thi^kly grown with bacteria, whereas the test tube with gel only shows bacterial growth in the uppermost layer. This shows that the powdered gel according to the present invention, when swollen, makes the pene-tration of bacteria very difficult or impossible.
Example 4.
A dry gel powder according to the present invention -~2-and produced as described in Example 1 was classified with a sieve, four fractions thereby beinq obtained.
Fraction 1 consisted of a portion which did not pass a sieve of 57~ apertures/cm~ (about 0.~5 mm. aperture width), fraction 2 consisted of particles which passed a 576 aperture sieve but were retained by a 900 aperture/
cm sieve (about 0.20 mm. aperture width), fraction 3 passed a 900 aperture sieve and was retained by a 1600 aperture sieve (about O.lS mm. aperture width) and fraction 4 consisted of particles which passed a 1600 aperture sieve.
For each of these our fractions and for the starting mixture, there was determined the water take-up for, in each case, 1 g. of powder in dependence upon the time, the results obtained being summarised in the Figure of the accompanying drawing which shows graphic-ally the water take-up in ml./g., plotted against the time in minutes. Curves 1 to 4 correspond to the water take-up of fractions 1 to 4 and curve 5 shows the water take-up of the non-fractionated mixture. The latter contained ~8.1% by weight of fraction 1, 9.4% by weight of fraction 2, 11.4% by weight of fraction 3 and 12.1%
by weight of fraction 4. As can be seen from the curves, the rate of water take-up in the case of fraction 4 was, in the initial phase, about twice as great as in the case of fraction 1, whereas the total water take-up after 5 minutes amounts to 38.3 and 34.3 g., respectively.
Claims (23)
1. Wound treating agent in powder form based on a swellable organic polymer, which comprises a cross-linked polymer of a hydrophilic acrylic or methacrylic acid derivative, which polymer is permeated by at least one gellable reagent selected from the group consisting of polysaccharide, protein and a poly-peptide, the agent being obtainable by polymerizing a hydrophilic acrylic or methacrylic acid derivative in the presence of said dissolved gellable reagent and of a cross-linking agent.
2. Wound treating agent according to claim 1, wherein the hydrophilic acrylic or methacrylic acid derivative is an amide or ester of said acid with an alkanol.
3. Wound treating agent according to claim 2, wherein said derivative contains one or more additional free hydroxyl groups.
4. Wound treating agent according to claim 1, 2 or 3, wherein the gellable reagent comprises agarose.
5. Wound treating agent according to claim 1, 2 or 3, wherein the gellable reagent comprises gelatine.
6. Wound treating agent according to claim 1, 2 or 3, comprising a gel containing 50 to 90% by weight of the polymerized acrylic or methacrylic acid derivative and 50 to 10% by weight of at least one gellable reagent selected from polysaccharide and protein.
7. Wound treating agent according to claim 1, 2 or 3, having a water uptake of at least 20 ml./g.
after swelling for two minutes in salt-free water.
after swelling for two minutes in salt-free water.
8. Wound treating agent according to claim 1, 2 or 3, enveloped in a semi-permeable membrane.
9. Wound treating agent according to claim 1, 2 or 3, having a particle size of which is from 0.05 mm to 0.5 mm.
10. Wound treating agent according to claim 1, comprising a gel containing 50 to 90% by weight of the polymerized acrylic or methacrylic acid derivative and 50 to 10% of said gellable reagent, said agent having a water uptake of at least 20 ml./g. after swelling for two minutes in salt-free water, and having a particle size of from 0.05 mm to 0.5 mm.
11. Wound treating agent according to claim 10, wherein said gellable reagent is agarose.
12. Wound treating agent according to claim 10, wherein said gellable reagent is gelatine.
13. Wound treating agent according to claim 10, 11 or 12, enveloped in a semi-permeable membrane.
14. A process for the production of a wound treating agent in powder form based on a swellable organic polymer, which comprises a cross-linked polymer of a hydrophilic acrylic or methacrylic acid derivative, which polymer is permeated by at least one gellable reagent selected from the group consisting of polysaccharide, protein and a polypeptide, the agent being obtainable by polymerizing a hydrophilic acrylic or methacrylic acid derivative in the presence of said dissolved gellable reagent and a cross-linking agent, comprising:
polymerizing a hydrophilic acrylic or meth-acrylic acid derivative in an aqueous solution of said at least one gellable reagent in the presence of said cross-linking agent and of a polymerization initiator, to produce a gel, and drying and pulverising said gel to a powder form.
polymerizing a hydrophilic acrylic or meth-acrylic acid derivative in an aqueous solution of said at least one gellable reagent in the presence of said cross-linking agent and of a polymerization initiator, to produce a gel, and drying and pulverising said gel to a powder form.
15. A process according to claim 14, wherein said gel is transparent.
16. A process according to claim 14, wherein the acrylic or methacrylic derivative used is an amide or an ester of said acid with an alkanol.
17. A process according to claim 16, wherein said derivative contains one or more free hydroxyl groups.
18. A process according to claim 14, 15 or 16, wherein said gellable reagent comprises agarose.
19. A process according to claim 14, 15 or 16, wherein said gellable reagent comprises gelatine.
20. A process according to claim 14, 15 or 16, wherein the gel is dried at a temperature of from 30 to 90°C.
21. A process according to claim 14, 15 or 16, wherein the gel is dried at a temperature of from 40 to 80°C.
22. A process according to claim 14, 15 or 16, wherein the gel is dried to a residual water content of less than 10% by weight.
23. Wound treating agent in powder form based on a swellable organic polymer, which comprises a cross-linked polymer of a hydrophilic acrylic or methacrylic acid derivative, which polymer is permeated by at least one gellable reagent selected from the group consisting of polysaccharide, protein and a poly-peptide, the agent being obtainable by polymerizing a hydrophilic acrylic or methacrylic acid derivative in the presence of said dissolved gellable reagent and of a cross-linking agent, produced by a process according to claim 14, 15 or 16.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803036033 DE3036033A1 (en) | 1980-09-24 | 1980-09-24 | POWDERED WOUND TREATMENT AND METHOD FOR THE PRODUCTION THEREOF |
| DEP3036033.9 | 1980-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1171787A true CA1171787A (en) | 1984-07-31 |
Family
ID=6112757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000386455A Expired CA1171787A (en) | 1980-09-24 | 1981-09-23 | Wound treating agent in powder form and process for its preparation |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4554156A (en) |
| EP (1) | EP0048323B1 (en) |
| JP (1) | JPS5782313A (en) |
| AR (1) | AR227931A1 (en) |
| AT (1) | ATE12894T1 (en) |
| AU (1) | AU527435B2 (en) |
| CA (1) | CA1171787A (en) |
| CS (1) | CS236470B2 (en) |
| DD (1) | DD201754A5 (en) |
| DE (2) | DE3036033A1 (en) |
| DK (1) | DK154805C (en) |
| ES (1) | ES8301640A1 (en) |
| FI (1) | FI72654C (en) |
| HU (1) | HU186784B (en) |
| NO (1) | NO153035C (en) |
| PL (1) | PL233144A1 (en) |
| ZA (1) | ZA816594B (en) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE82511T1 (en) * | 1982-04-22 | 1992-12-15 | Squibb & Sons Inc | GRANULES FOR USE IN THE TREATMENT OF WOUNDS. |
| US4652443A (en) * | 1983-06-07 | 1987-03-24 | Japan Atomic Energy Research Institute | Slow-release composite and process for producing the same |
| GB2148901A (en) * | 1983-10-04 | 1985-06-05 | Johnson & Johnson | Protein/polysaccharide complexes |
| JPS61501155A (en) * | 1984-02-03 | 1986-06-12 | スコツト・ペ−パ−・カンパニ− | Modified polysaccharide material |
| SE460017B (en) * | 1984-03-14 | 1989-09-04 | Landstingens Inkopscentral | BACTERY-ADDRESSING COMPOSITION IN WATER-SOLUBLE FORM |
| GB8422950D0 (en) * | 1984-09-11 | 1984-10-17 | Warne K J | Hydrogel |
| US5022413A (en) * | 1988-04-21 | 1991-06-11 | Spina Jr Joseph | Intralenticular cataract surgical procedure |
| US5438076A (en) * | 1988-05-03 | 1995-08-01 | Perio Products, Ltd. | Liquid polymer composition, and method of use |
| US5160737A (en) * | 1988-05-03 | 1992-11-03 | Perio Products Ltd. | Liquid polymer composition, and method of use |
| DE3903672C1 (en) * | 1989-02-08 | 1990-02-01 | Lohmann Gmbh & Co Kg | |
| US5035890A (en) * | 1989-04-10 | 1991-07-30 | Dow Corning Corporation | Emulsifier-free hand and body lotion |
| US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
| US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US7435425B2 (en) | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
| US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
| US7871637B2 (en) | 1996-08-27 | 2011-01-18 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
| US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| WO2003057072A2 (en) * | 2001-12-31 | 2003-07-17 | Ares Laboratories, Llc | Hemostatic compositions and methods for controlling bleeding |
| GB2384187A (en) * | 2002-01-22 | 2003-07-23 | Johnson & Johnson Medical Ltd | Particulate wound dressing |
| CA2480889C (en) | 2002-03-14 | 2011-11-15 | Medrx Co., Ltd. | External preparation for wounds |
| US8834864B2 (en) | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
| US7927626B2 (en) * | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| US8252339B2 (en) * | 2006-04-11 | 2012-08-28 | Massachusetts Institute Of Technology | Medical treatment applications of swellable and deformable microspheres |
| BRPI0712088B8 (en) | 2006-05-31 | 2021-06-22 | Baxter Healthcare Sa | use of a non-porous, fluid-tight, multi-layered, microscopic collagen lamina biomatrix |
| TWI436793B (en) | 2006-08-02 | 2014-05-11 | Baxter Int | Rapidly acting dry sealant and methods for use and manufacture |
| US8114159B2 (en) | 2006-11-20 | 2012-02-14 | Depuy Spine, Inc. | Anterior spinal vessel protector |
| JP2011500237A (en) | 2007-10-30 | 2011-01-06 | バクスター・インターナショナル・インコーポレイテッド | Use of regenerative biofunctional collagen biomatrix to treat visceral or cavity wall defects |
| US20100311026A1 (en) | 2009-06-03 | 2010-12-09 | Tomes Jennifer E | Catheter Tray, Packaging System, and Associated Methods |
| US8448786B2 (en) | 2009-06-30 | 2013-05-28 | Medline Industries, Inc. | Catheter tray, packaging system, instruction insert, and associated methods |
| US8678190B2 (en) | 2009-06-30 | 2014-03-25 | Medline Industries, Inc. | Catheter tray, packaging system, instruction insert, and associated methods |
| US8631935B2 (en) | 2009-06-03 | 2014-01-21 | Medline Industries, Inc. | Catheter tray, packaging system, and associated methods |
| RU2545810C2 (en) | 2008-02-29 | 2015-04-10 | Ферросан Медикал Дивайсиз А/С | Device for fastening haemostasis and/or wound healing |
| US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
| EP2442835B1 (en) | 2009-06-16 | 2014-12-10 | Baxter International Inc | Hemostatic sponge |
| JP2013514093A (en) | 2009-12-16 | 2013-04-25 | バクスター・インターナショナル・インコーポレイテッド | Hemostatic sponge |
| SA111320355B1 (en) | 2010-04-07 | 2015-01-08 | Baxter Heathcare S A | Hemostatic sponge |
| CN102917691A (en) | 2010-06-01 | 2013-02-06 | 巴克斯特国际公司 | Process for making dry and stable hemostatic compositions |
| CN103037845B (en) | 2010-06-01 | 2015-11-25 | 巴克斯特国际公司 | For the preparation of the method for dry, stable hemostatic composition |
| CN103037847B (en) | 2010-06-01 | 2016-01-20 | 巴克斯特国际公司 | For the preparation of the method for dry, stable hemostatic composition |
| CN103957948B (en) | 2011-10-11 | 2016-10-26 | 巴克斯特国际公司 | Hemostatic composition |
| JP6195569B2 (en) | 2011-10-11 | 2017-09-13 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | Hemostatic composition |
| SA112330957B1 (en) | 2011-10-27 | 2015-08-09 | باكستر انترناشونال انك. | Hemostatic compositions |
| JP6241624B2 (en) | 2012-03-06 | 2017-12-06 | フェロサン メディカル デバイシーズ エイ／エス | Pressurized container containing hemostatic paste |
| CA2874290C (en) | 2012-06-12 | 2020-02-25 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| CA2912357C (en) | 2013-06-21 | 2019-12-31 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| AU2014361291B2 (en) | 2013-12-11 | 2017-11-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| CN106999621B (en) | 2014-10-13 | 2020-07-03 | 弗罗桑医疗设备公司 | Dry composition for hemostasis and wound healing |
| AU2015371184B2 (en) | 2014-12-24 | 2020-06-25 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| WO2017005590A1 (en) | 2015-07-03 | 2017-01-12 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| EP3790600B1 (en) | 2018-05-09 | 2023-12-27 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
| CN114306242B (en) * | 2021-12-29 | 2023-04-25 | 广州佰斯伦医疗器械有限公司 | Liposome particles containing growth factor nanogel and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3618213A (en) * | 1970-04-27 | 1971-11-09 | Nat Patent Dev Corp | Denture liners |
| SE452109B (en) * | 1973-01-29 | 1987-11-16 | Pharmacia Ab | SCIENTIFIC CLEANER EXTENDED SARYTOR |
| US3963685A (en) * | 1974-05-13 | 1976-06-15 | Abrahams Robert A | Alcohol soluble hydrophilic polymer via aqueous polymerization |
| US4090013A (en) * | 1975-03-07 | 1978-05-16 | National Starch And Chemical Corp. | Absorbent composition of matter |
| DE2725261C2 (en) * | 1977-06-03 | 1986-10-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Transparent liquid dressing material, its manufacture and use |
-
1980
- 1980-09-24 DE DE19803036033 patent/DE3036033A1/en not_active Withdrawn
-
1981
- 1981-07-21 EP EP81105755A patent/EP0048323B1/en not_active Expired
- 1981-07-21 DE DE8181105755T patent/DE3170119D1/en not_active Expired
- 1981-07-21 AT AT81105755T patent/ATE12894T1/en not_active IP Right Cessation
- 1981-07-31 AR AR286315A patent/AR227931A1/en active
- 1981-09-02 DK DK388781A patent/DK154805C/en not_active IP Right Cessation
- 1981-09-15 ES ES505512A patent/ES8301640A1/en not_active Expired
- 1981-09-16 CS CS816830A patent/CS236470B2/en unknown
- 1981-09-18 FI FI812920A patent/FI72654C/en not_active IP Right Cessation
- 1981-09-18 AU AU75487/81A patent/AU527435B2/en not_active Ceased
- 1981-09-21 JP JP56147984A patent/JPS5782313A/en active Granted
- 1981-09-23 PL PL23314481A patent/PL233144A1/en unknown
- 1981-09-23 DD DD81233513A patent/DD201754A5/en unknown
- 1981-09-23 ZA ZA816594A patent/ZA816594B/en unknown
- 1981-09-23 CA CA000386455A patent/CA1171787A/en not_active Expired
- 1981-09-23 NO NO813236A patent/NO153035C/en unknown
- 1981-09-23 HU HU812750A patent/HU186784B/en unknown
-
1984
- 1984-11-26 US US06/674,366 patent/US4554156A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NO813236L (en) | 1982-03-25 |
| DK154805C (en) | 1989-06-05 |
| FI812920L (en) | 1982-03-25 |
| ATE12894T1 (en) | 1985-05-15 |
| DE3170119D1 (en) | 1985-05-30 |
| NO153035C (en) | 1986-01-08 |
| JPS5782313A (en) | 1982-05-22 |
| AU7548781A (en) | 1982-04-01 |
| CS236470B2 (en) | 1985-05-15 |
| DE3036033A1 (en) | 1982-05-06 |
| DK154805B (en) | 1988-12-27 |
| FI72654C (en) | 1987-07-10 |
| EP0048323A1 (en) | 1982-03-31 |
| AU527435B2 (en) | 1983-03-03 |
| EP0048323B1 (en) | 1985-04-24 |
| HU186784B (en) | 1985-09-30 |
| DD201754A5 (en) | 1983-08-10 |
| ES505512A0 (en) | 1983-02-01 |
| PL233144A1 (en) | 1983-01-17 |
| AR227931A1 (en) | 1982-12-30 |
| ZA816594B (en) | 1982-09-29 |
| FI72654B (en) | 1987-03-31 |
| JPS6134829B2 (en) | 1986-08-09 |
| DK388781A (en) | 1982-03-25 |
| ES8301640A1 (en) | 1983-02-01 |
| NO153035B (en) | 1985-09-30 |
| US4554156A (en) | 1985-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1171787A (en) | Wound treating agent in powder form and process for its preparation | |
| US11235083B2 (en) | Composite hydrogel and metal silicate wound healing material | |
| EP0663212B1 (en) | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | |
| CA2412804C (en) | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | |
| US4587284A (en) | Absorbent polymer material and its preparation | |
| CA1328206C (en) | Wound dressing | |
| CN110152051B (en) | Water-absorbing burn wound antibacterial dressing and preparation method and application thereof | |
| WO1998051408A1 (en) | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strenght, and superabsorbent properties | |
| GB1594389A (en) | Dressing material for wounds | |
| EP0586260A1 (en) | Alginate gel | |
| CN105228658A (en) | A kind of medical dressing hydrogel compound fabric and its preparation method and application | |
| Bardajee et al. | A superabsorbent hydrogel network based on poly ((2-dimethylaminoethyl) methacrylate) and sodium alginate obtained by γ-radiation: synthesis and characterization | |
| KR100440239B1 (en) | Method for the preparation of hydrogels for wound dressings | |
| Wang et al. | A study of the swelling and model protein release behaviours of radiation-formed poly (N-vinyl 2-pyrrolidone-co-acrylic acid) hydrogels | |
| GB2431104A (en) | Microgel particles grafted to a substrate | |
| JP2011001482A (en) | Polymer gel, polymer gel dispersion, polymer gel composite, and method for producing the same | |
| Kaetsu et al. | Controlled release of multi-component cytotoxic agents from radiation polymerized composites | |
| CA1266767A (en) | Absorbent polymer material and its preparation | |
| WO2010067378A2 (en) | Hydrogel composition | |
| Xu et al. | Etamsylate loaded oxidized Konjac glucomannan-ε-polylysine injectable hydrogels for rapid hemostasis and wound healing | |
| AU772546B2 (en) | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties | |
| RU2091082C1 (en) | Wound coating and a method of its preparing | |
| CA1116519A (en) | Transparent liquid dressing material, its manufacture and use | |
| Rosiak et al. | Radiation Gelation of Hydrogels and their Applications | |
| Mechain et al. | Immobilization of asparaginase in radiation cured, thermally reversible hydrogels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |